Top

Published in:

01-04-2013 | Original Article

Low RKIP expression associates with poor prognosis in bladder cancer patients

Authors: Julieta Afonso, Adhemar Longatto-Filho, Olga Martinho, Francisco Lobo, Teresina Amaro, Rui M. Reis, Lúcio L. Santos

Published in: Virchows Archiv | Issue 4/2013

Abstract

Urothelial bladder cancer (UBC) is a heterogeneous type of disease. It is urgent to screen biomarkers of tumour aggressiveness in order to clarify the clinical behaviour and to personalize therapy in UBC patients. Raf kinase inhibitory protein (RKIP) is a metastasis suppressor, and its downregulation is associated with metastatic events in an increasing number of solid tumours. We evaluated the clinical and prognostic significance of RKIP expression in patients with high risk of progression UBC. Using immunohistochemistry, we determined RKIP expression levels in a series of 81 patients with high-grade pT1/pTis or muscle-invasive UBC. Staining of CD31 and D2-40 was used to assess blood and lymphatic vessels, in order to distinguish between blood and lymphatic vessel invasion (LVI). We found that 90 % of pT1/pTis tumours, 94 % of non-muscle invasive papillary tumours and 76 % of the cases without LVI occurrence expressed RKIP in >10 % of cells. In this group, we observed a subgroup of tumours (42 %) in which the tumour centre was significantly more intensely stained than the invasion front. This heterogeneous pattern was observed in 63 % of the cases with LVI. Low RKIP expression was associated with poorer 5-year disease-free and overall survival rates, and remained as an independent prognostic factor for disease-free survival. Loss of RKIP expression may be an important prognostic factor for patients with high risk of progression bladder cancer.

Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239–249PubMedCrossRef

Sternberg CN, Donat SM, Bellmunt J et al (2007) Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69(Suppl 1):62–79PubMedCrossRef

Sternberg CN (2006) Muscle invasive and metastatic bladder cancer. Ann Oncol 17(Suppl 10):23–30CrossRef

Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290PubMedCrossRef

Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef

Stoehr R, Brinkmann A, Filbeck T et al (2004) No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. Oncol Rep 11(Suppl 1):137–141PubMed

Boulalas I, Zaravinos A, Delakas D, Spandidos DA (2009) Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int J Biol Markers 24(Suppl 1):17–21PubMed

Karlou M, Saetta AA, Korkolopoulou P et al (2009) Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology 41(Suppl 4):327–334PubMedCrossRef

Zaravinos A, Chatziioannou M, Lambrou GI et al (2011) Implication of RAF and RKIP genes in urinary bladder cancer. Pathol Oncol Res 17(Suppl2): 181–190

10.

Klysik J, Theroux SJ, Sedivy JM, Moffit JS, Boekelheide K (2008) Signaling crossroads: the function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal 20:1–9PubMedCrossRef

11.

Hellmann J, Rommelspacher H, Mühlbauer E, Wernicke C (2010) Raf kinase inhibitor protein enhances neuronal differentiation in human SH-SY5Y cells. Dev Neurosci 32(1):33–46PubMedCrossRef

12.

Eves EM, Shapiro P, Naik K et al (2006) Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell 23(4):561–574PubMedCrossRef

13.

Al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W (2011) RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst 7(3):928–941PubMedCrossRef

14.

Yeung KC, Rose DW, Dhillon AS et al (2001) Raf kinase inhibitor protein interacts witw NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 21:7207–7217PubMedCrossRef

15.

Kim SY, Park SG, Jung H et al (2011) RKIP downregulation induces the HBx-mediated Raf-1 mitochondrial translocation. J Microbiol Biotechnol 21(5):525–528PubMedCrossRef

16.

Baritaki S, Chapman A, Yeung K et al (2009) Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 28(40):3573–3485PubMedCrossRef

17.

Wu K, Bonavida B (2009) The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 29(3):241–254PubMedCrossRef

18.

Zhu S, Mc Henry KT, Lane WS, Fenteany G (2005) A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. Chem Biol 12(9):981–991PubMedCrossRef

19.

Yeung K, Janosch P, McFerran B et al (2000) Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 20(9):3079–3085PubMedCrossRef

20.

Tang H, Park S, Sun SC et al (2010) RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex. FEBS Lett 584(4):662–668PubMedCrossRef

21.

Lorenz K, Lohse MJ, Quitterer U et al (2003) Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574–579PubMedCrossRef

22.

Al-Mulla F, Bitar MS, Al-Maghrebi M et al (2011) Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β. Cancer Res 71(4):1334–1343PubMedCrossRef

23.

Fu Z, Smith PC, Zhang L (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95:878–879PubMedCrossRef

24.

Hagan S, Al-Mulla F, Mallon E (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 11:7392–7397PubMedCrossRef

25.

Al-Mulla F, Hagan S, Behbehani AI (2006) Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 24:5672–5679PubMedCrossRef

26.

Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK (2004) Reduction of Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64:5186–5192PubMedCrossRef

27.

Afonso J, Santos LL, Amaro T, Lobo F, Longatto-Filho A (2009) The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion—the prognostic contribution of related molecular markers. Histopathology 55:514–524PubMedCrossRef

28.

Amin MB, Srigley JR, Grignon DJ et al (2005) Urinary bladder cancer protocols and checklists. College of American Pathologists, Northfield

29.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual. Springer, New York

30.

Mostofi CJ, Davis CJ, Sesterhenn IA (1999) World Health Organization, International Histological Classification of Tumours. Histological typing of urinary bladder tumours. Springer, BerlinCrossRef

31.

Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) World Health Organization Classification of Tumours. Pathology and genetics of tumours of the urinary system and male genital organ. IARC Press, Lyon

32.

Martinho O, Gouveia A, Silva P et al (2009) Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch 455(Suppl 3):277–284PubMedCrossRef

33.

Martinho O, Faloppa CC, Neto CS et al (2012) Loss of RKIP expression during the carcinogenic evolution of endometrial cancer. J Clin Pathol 65(Suppl 2):122–128PubMedCrossRef

34.

Martinho O, Granja S, Jaraquemada T et al (2012) Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. PLoS One 7(1):e30769PubMedCrossRef

35.

Bevilacqua E, Frankenberger CA, Rosner MR (2012) RKIP suppresses breast cancer metastasis to the bone by regulating stroma-associated genes. Int J Breast Cancer 2012:124704PubMed

36.

Hao C, Wei S, Tong Z et al (2012) The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro. Tumour Biol 33(Suppl 4):1159–1167PubMedCrossRef

37.

Xinzhou H, Ning Y, Ou W et al (2011) RKIP inhibits the migration and invasion of human prostate cancer PC-3 M cells through regulation of extracellular matrix. Mol Biol (Mosk) 45(Suppl 6):1004–1011

38.

Beshir AB, Ren G, Magpusao AN et al (2010) Raf kinase inhibitor protein suppresses nuclear factor-κB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett 299(Suppl 2):137–149PubMedCrossRef

39.

Beach S, Tang H, Park S et al (2008) Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 27(Suppl 15):2243–2248PubMedCrossRef

40.

Thuault S, Valcourt U, Petersen M et al (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial–mesenchymal transition. J Cell Biol 174(2):175–183PubMedCrossRef

41.

Lee YS, Dutta A (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21(9):1025–1030PubMedCrossRef

42.

Dangi-Garimella S, Yun J, Eves EM et al (2009) Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 28(4):347–358PubMedCrossRef

43.

Yun J, Frankenberger CA, Kuo WL et al (2011) Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J 30(21):4500–4514PubMedCrossRef

44.

Zhang L, Fu Z, Binkley C et al (2004) Raf kinase inhibitory protein inhibits beta-cell proliferation. Surgery 136:708–715PubMedCrossRef

45.

Li HZ, Wang Y, Gao Y et al (2008) Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 6(Suppl 6):917–928PubMedCrossRef

46.

Wang J, Yang YH, Wang AQ (2010) Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Med Oncol 27(Suppl 2):219–223PubMedCrossRef

47.

Lee HC, Tian B, Sedivy JM, Wands JR, Kim M (2006) Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131(Suppl 4):1208–1217PubMedCrossRef

48.

Hu CJ, Zhou L, Zhang J, Huang C, Zhang GM (2011) Immunohistochemical detection of Raf kinase inhibitor protein in normal cervical tissue and cervical cancer tissue. J Int Med Res 39(Suppl 1):229–237PubMed

49.

Kim HS, Won KY, Kim GY et al (2012) Reduced expression of Raf-1 kinase inhibitory protein predicts regional lymph node metastasis and shorter survival in esophageal squamous cell carcinoma. Pathol Res Pract 208(Suppl 5):292–299PubMedCrossRef

50.

Kim HS, Lee SH, Won KY (2012) Expression of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of Vater. Virchows Arch 460(Suppl 1):61–68PubMedCrossRef

51.

Fu Z, Kitagawa Y, Shen R et al (2006) Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66:248–256PubMedCrossRef

52.

Chatterjee D, Sabo E, Tavares R, Resnick MB (2008) Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 14(Suppl 10):2994–3001PubMedCrossRef

53.

Gao C, Pang L, Ren C, Ma T (2012) Prognostic value of raf kinase inhibitor protein in esophageal squamous cell carcinoma. Pathol Oncol Res 18(Suppl 2):471–477PubMedCrossRef

54.

Kim HS, Kim GY, Lim SJ, Kim YW (2010) Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 42(Suppl 7):655–660PubMedCrossRef

55.

Kim HS, Kim GY, Lim SJ, Park YK, Kim YW (2010) Reduced expression of Raf-1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma. Hum Pathol 41(Suppl 11):1609–1616PubMedCrossRef

56.

Chatterjee D, Bai Y, Wang Z et al (2004) RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279(Suppl 17):17515–17523PubMedCrossRef

57.

Ruan L, Wang GL, Yi H, Chen Y et al (2010) Raf kinase inhibitor protein correlates with sensitivity of nasopharyngeal carcinoma to radiotherapy. J Cell Biochem 110(Suppl 4):975–981PubMedCrossRef

58.

Woods Ignatoski KM, Grewal NK, Markwart SM et al (2008) Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys 72(Suppl 1):153–160PubMedCrossRef

59.

Al-Mulla F, Hagan S, Al-Ali W (2008) Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol 61(Suppl 4):524–529PubMedCrossRef

60.

Minoo P, Baker K, Goswami R (2006) Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut 55(Suppl 10):1467–1474PubMedCrossRef

61.

Ren G, Baritaki S, Marathe H et al (2012) Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 72(12):3091–3104PubMedCrossRef

62.

Al-Mulla F, Bitar MS, Feng J, Park S, Yeung KC (2012) A new model for raf kinase inhibitory protein induced chemotherapeutic resistance. PLoS One 7(1):e29532PubMedCrossRef

Title: Low RKIP expression associates with poor prognosis in bladder cancer patients
Authors: Julieta Afonso
Adhemar Longatto-Filho
Olga Martinho
Francisco Lobo
Teresina Amaro
Rui M. Reis
Lúcio L. Santos
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 4/2013
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-013-1388-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Low RKIP expression associates with poor prognosis in bladder cancer patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing

Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma

Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens

Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression

Detection of Epstein–Barr virus-infected lymphoid cells in nasal mucosa or nasopharynx: appearances can be deceptive

Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS)